Ida van der Peet

Dr. Ida van der Peet

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
CCChilam Chan
Chilam Chan
JJJ.H. Marco Jansen
J.H. Marco Jansen
IHIlona S.T. Hendriks
Ilona S.T. Hendriks
IPIda van der Peet
Ida van der Peet
MVMeggy E.L. Verdonschot
Meggy E.L. Verdonschot
POPatricia A Olofsen
Patricia A Olofsen
EGFR plays an essential role in cellular signaling pathways that regulate cell growth, proliferation, and survival and is often dysregulated in cancer. Several monoclonal IgG antibodies have been clinically tested over the years, which exert their function via blocking the ligand binding domain (thereby inhibiting downstream signaling) and inducing Fc-related effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). However, these IgG antibodies do not optimally recruit neutrophils, which are the most abundant white blood cell population in humans. Therefore, we reformatted six therapeutic EGFR antibodies (cetuximab, panitumumab, nimotuzumab, necitumumab, zalutumumab, and matuzumab) into the IgA3.0 format, which is an IgA2 isotype adapted for clinical application. Reformatting these antibodies preserved Fab-mediated functions such as EGFR binding, growth inhibition, and ligand blockade. In addition, whole leukocyte ADCC was significantly increased when using this panel of IgA3.0 antibodies compared with their respective IgG counterparts, with no major differences between IgA3.0 antibodies. In vivo, IgA3.0 matuzumab outperformed the other antibodies, resulting in the strongest suppression of tumor outgrowth in a long intraperitoneal model. We showed that neutrophils are important for the suppression of tumor outgrowth. IgA3.0 matuzumab exhibited reduced receptor internalization compared with the other antibodies, possibly accounting for its superior in vivo Fc-mediated tumor cell killing efficacy. In conclusion, reformatting EGFR antibodies into an IgA3.0 format increased Fc-mediated killing while retaining Fab-mediated functions and could therefore be a good alternative for the currently available antibody therapies.

4 September 2024
Verified
Other
Open access
PDF file
CCChilam Chan
Chilam Chan
JJJ.H. Marco Jansen
J.H. Marco Jansen
IHIlona S.T. Hendriks
Ilona S.T. Hendriks
IPIda van der Peet
Ida van der Peet
MVMeggy E.L. Verdonschot
Meggy E.L. Verdonschot
POPatricia A Olofsen
Patricia A Olofsen
Supplementary Figure 5: Tumor outgrowth in A431-luc2 tumor-bearing mice treated with IgA3.0 Matuzumab.

4 September 2024
Verified
Other
Open access
PDF file
CCChilam Chan
Chilam Chan
JJJ.H. Marco Jansen
J.H. Marco Jansen
IHIlona S.T. Hendriks
Ilona S.T. Hendriks
IPIda van der Peet
Ida van der Peet
MVMeggy E.L. Verdonschot
Meggy E.L. Verdonschot
POPatricia A Olofsen
Patricia A Olofsen
Supplementary Figure 4: IgA3.0 EGFR mitigated tumor burden in a short intraperitoneal EL4 tumor model.

4 September 2024
Verified
Other
Open access
PDF file
CCChilam Chan
Chilam Chan
JJJ.H. Marco Jansen
J.H. Marco Jansen
IHIlona S.T. Hendriks
Ilona S.T. Hendriks
IPIda van der Peet
Ida van der Peet
MVMeggy E.L. Verdonschot
Meggy E.L. Verdonschot
POPatricia A Olofsen
Patricia A Olofsen
Supplementary Figure 8: Internalization of IgA3.0 EGFR antibodies.

4 September 2024
Verified
Other
Open access
PDF file
CCChilam Chan
Chilam Chan
JJJ.H. Marco Jansen
J.H. Marco Jansen
IHIlona S.T. Hendriks
Ilona S.T. Hendriks
IPIda van der Peet
Ida van der Peet
MVMeggy E.L. Verdonschot
Meggy E.L. Verdonschot
POPatricia A Olofsen
Patricia A Olofsen
Supplementary Figure 7: Binding kinetics of IgA3.0 EGFR antibodies.

4 September 2024
Verified
Other
Open access
PDF file
CCChilam Chan
Chilam Chan
JJJ.H. Marco Jansen
J.H. Marco Jansen
IHIlona S.T. Hendriks
Ilona S.T. Hendriks
IPIda van der Peet
Ida van der Peet
MVMeggy E.L. Verdonschot
Meggy E.L. Verdonschot
POPatricia A Olofsen
Patricia A Olofsen
Supplementary Figure 1: Purification of IgA3.0 EGFR mAbs.